CORRECTION
Clarification of Reporting of Potential Conflicts of Interest in 2 Articles: In the Viewpoint titled “Ten Steps the Federal Government Should Take Now to Reverse the Opioid Addiction Epidemic” published in the October 24, 2017, issue and in the Letter titled “Government Actions to Curb the Opioid Epidemic—Reply” published in the April 17, 2018, issue of JAMA, an author’s potential conflicts of interest disclosure statement was incomplete. In the Viewpoint,1 the disclosure statement should have read: “Dr Kolodny reported being the executive director of Physicians for Responsible Opioid Prescribing; serving as a medical expert for states and counties that have filed suits against opioid manufacturers and as an expert witness in malpractice cases involving opioid prescribing; and being the former chief medical officer of Phoenix House, a nonprofit addiction treatment agency.”


Error in Text: The Editorial titled “Psychological Consequences of Admission to the ICU: Helping Patients and Families”1 published in the July 16, 2019, issue of JAMA had typographical errors in the text, including that the P value after the description of the higher risk of mortality in the intensive care unit among patients in the intervention group than in the control group was P > .01 rather than P < .01. This article has been corrected online.


Guidelines for Letters
Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.